Federal Register / Vol. 72, No. 37 / Monday, February 26, 2007 / Notices 8385 

knowledge that it inhibits DNA 

synthesis and is cytotoxic, and (3) 

published evidence of reproductive and 

developmental toxicity in rodents. 

The CERHR convened an expert panel 

on January 24–26, 2007, to review and 

revise the draft expert panel report and 

reach conclusions regarding whether 

exposure to hydroxyurea is a hazard to 

human development or reproduction. 

The expert panel also identified data 

gaps and research needs. Prior to the 

meeting, CERHR solicited public 

comment on the draft expert panel 

report (Federal Register Vol. 71, No. 199 

pp. 60746–60748). 

Following receipt of public comments 

on the hydroxyurea expert panel report, 

CERHR staff will prepare the NTP–

CERHR monograph. NTP–CERHR 

monographs are divided into four major 

sections: (1) The NTP Brief which 

provides the NTP’s interpretation of the 

potential for the chemical to cause 

adverse reproductive and/or 

developmental effects in exposed 

humans, (2) a roster of expert panel 

members, (3) the final expert panel 

report, and (4) public comments 

received on that report. The NTP Brief 

is based on the expert panel report, 

public comments on that report, public 

and peer review comments on the draft 

NTP Brief, and any new information 

that became available after the expert 

panel meeting. 

Request for Comments 

CERHR invites written public 

comments on the hydroxyurea expert 

panel report. Written comments should 

be sent to Dr. Michael Shelby at the 

address provided above. Persons 

submitting written comments are asked 

to include their name and contact 

information (affiliation, mailing address, 

telephone and facsimile numbers, email, and sponsoring organization, if 

any). All comments received will be 

posted on the CERHR website and will 

be included in the NTP–CERHR 

monograph on hydroxyurea. The NTP 

will consider all public comments 

during preparation of the NTP Brief. 

Background Information on CERHR 

The NTP established CERHR in June 

1998 [Federal Register, December 14, 

1998 (Vol. 63, No. 239, pp. 68782)]. 

CERHR is a publicly accessible resource 

for information about adverse 

reproductive and/or developmental 

health effects associated with exposure 

to environmental and/or occupational 

exposures. Expert panels conduct 

scientific evaluations of agents selected 

by CERHR in public forums. 

CERHR invites the nomination of 

agents for review or scientists for its 

expert registry. Information about 

CERHR and the nomination process can 

be obtained from its Web site (http:// 

cerhr.niehs.nih.gov) or by contacting Dr. 

Shelby (see ADDRESSES above). CERHR 

selects chemicals for evaluation based 

upon several factors including 

production volume, potential for human 

exposure from use and occurrence in 

the environment, extent of public 

concern, and extent of data from 

reproductive and developmental 

toxicity studies. 

CERHR follows a formal, multi-step 

process for review and evaluation of 

selected chemicals. The formal 

evaluation process was published in the 

Federal Register notice July 16, 2001 

(Vol. 66, No. 136, pp 37047–37048) and 

is available on the CERHR Web site 

under ‘‘About CERHR’’ or in printed 

copy from CERHR. 

Dated: February 12, 2007. 

Samuel H. Wilson, 

Deputy Director, National Institute of 

Environmental Health Sciences and National 

Toxicology Program. 

[FR Doc. E7–3151 Filed 2–23–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60 Day–07–0274] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–5960 and 

send comments to Joan Karr, CDC 

Acting Reports Clearance Officer, 1600 

Clifton Road, MS–D74, Atlanta, GA 

30333 or send an e-mail to 

omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

CDC Model Performance Evaluation 

Program (MPEP) (0920–0274)—

Revision—National Center for 

Preparedness, Detection, and Control of 

Infectious Diseases (proposed) 

(NCPDCID), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

CDC is requesting OMB approval of a 

revision to its data collection, the CDC 

Model Performance Evaluation Program 

(MPEP). CDC originally implemented 

MPEP in 1986 to evaluate the 

performance of laboratories conducting 

testing to detect human 

immunodeficiency virus type 1 (HIV–1) 

antibody (Ab). CDC is requesting a 3- 

year approval for this data collection. 

In this program, respondents receive 2 

shipments of specimens per year. 

Respondents test the specimens in their 

laboratory/testing site and report their 

results either using a report booklet or 

on-line. CDC provides the respondent 

with a report containing the analysis of 

the laboratory test results reported to 

CDC. Participation in this program is 

voluntary and provides the respondents 

an opportunity to (1) assure accurate 

tests are being provided by the 

laboratory/testing site through external 

quality assessment; (2) improve testing 

quality through self-evaluation in a 

nonregulatory environment; (3) test well 

characterized samples from a source 

outside the test kit manufacturer; (4) 

discover potential testing problems so 

that procedures can be adjusted to 

eliminate them; (5) compare of testing 

results with others at a national and 

international level; and (6) consult with 

CDC staff to discuss testing issues. 

In this request, CDC proposes to make 

the following revisions to the currently 

approved data collection: 

• Addition of a Name and Address 

change form to report changes for the 

MPEP manager and coordinator at the 

respondent laboratory; 

• Inclusion of additional test kit 

manufacturers approved by the FDA 

since previous OMB approval; and 

• Elimination of reporting HIV–1 

RNA Viral Load and CD4+ T-cell 

determinations. 

All respondents are MPEP affiliated 

laboratories. 


ycherry on PROD1PC64 with NOTICES
8386 Federal Register / Vol. 72, No. 37 / Monday, February 26, 2007 / Notices 

There is no cost to respondents other 

than their time. 

ESTIMATE OF ANNUALIZED BURDEN HOURS

Respondents 

(type of form) 

Number of 

respondents 

Frequency of 

response 

Average time 

per response 

Annual burden 

(in hours) 

New Enrollees .......................................................................................... 100 1 3/60 5 

Laboratory Change Form ........................................................................ 20 1 3/60 1 

Laboratory Test Result Form ................................................................... 754 2 10/60 251 

Total .................................................................................................. .......................... .......................... .......................... 257 

Dated: February 20, 2007. 

Joan F. Karr, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E7–3167 Filed 2–23–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel: Occupational Safety 

and Health Research Member Conflict 

Review, Program Announcement 

Number (PA) 04–038 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following Meeting of the 

aforementioned committee: 

Time and Date: 1 p.m.–4 p.m., March 14, 

2007 (Closed). 

Place: National Institute for Occupational 

Safety and Health, 626 Cochrans Mill Road, 

Pittsburgh, PA 15236. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters to be Discussed: The meeting will 

include the review, discussion, and 

evaluation of research grant applications in 

response to PA 04–038, ‘‘Occupational Safety 

and Health Research Member Conflict 

Review.’’

Contact Person for More Information: 

George Bockosh, Designated Federal Officer, 

National Institute for Occupational Safety 

and Health, 626 Cochrans Mill Road, 

Pittsburgh, PA 30333, telephone 

412.386.6465. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: February 20, 2007. 

Elaine L. Baker, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E7–3184 Filed 2–23–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; NEI Mentored 

Training Grant Applications (K series). 

Date: February 26, 2007. 

Time: 10 a.m. to 11 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Eye Institute, 5635 Fishers 

Lane, Suite 1300, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Anne E. Schaffner, PhD, 

Scientific Review Administrator, Division of 

Extramural Research, National Eye Institute, 

5635 Fishers Lane, Suite 1300, MSC 9300, 

Bethesda, MD 20892–9300. (301) 451–2020, 

aes@nei.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; NEI Epidemiology, 

Genetics and Data Analysis Grant 

Applications. 

Date: March 22, 2007. 

Time: 8:30 a.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Houmam H. Araj, PhD, 

Scientific Review Administrator, Division of 

Extramural Research, National Eye Institute, 

NIH, 5635 Fishers Lane, Suite 1300, 

Bethesda, MD 20892–9602, 301–451–2020, 

haraj@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision research, 

National Institutes of Health, HHS. 

Dated: February 15, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–831 Filed 2–23–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel; Biostatistical Training Program in 

Genetics and Public Health. 

Date: March 9, 2007. 

Time: 8 a.m. to 6 p.m. 


ycherry on PROD1PC64 with NOTICES